CH374695A - Verfahren zur Herstellung von Blutplasmaersatzmitteln - Google Patents

Verfahren zur Herstellung von Blutplasmaersatzmitteln

Info

Publication number: CH374695A
Authority: CH; Switzerland
Prior art keywords: solution; isocyanate; crosslinking; molecular size; degradation
Prior art date: 1958-01-22

Application number

CH6857359A

Other languages

German (de)

English (en)

Inventor

Fritz Dr Lindner

Josef Dr Schmidt-Thome

Original Assignee

Hoechst Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1958-01-22

Filing date

1959-01-20

Publication date

1964-01-31

1958-01-22 Priority claimed from DEF24857A external-priority patent/DE1118792B/de

1958-06-07 Priority claimed from DEF25921A external-priority patent/DE1155134B/de

1959-01-20 Application filed by Hoechst Ag filed Critical Hoechst Ag

1964-01-31 Publication of CH374695A publication Critical patent/CH374695A/de

Links

238000000034 method Methods 0.000 title claims description 20
239000003058 plasma substitute Substances 0.000 title claims description 9
210000002381 plasma Anatomy 0.000 title claims description 8
230000008569 process Effects 0.000 title claims description 6
238000004519 manufacturing process Methods 0.000 title claims description 4
239000012948 isocyanate Substances 0.000 claims description 23
150000002513 isocyanates Chemical class 0.000 claims description 23
238000004132 cross linking Methods 0.000 claims description 17
239000000047 product Substances 0.000 claims description 16
230000015556 catabolic process Effects 0.000 claims description 13
238000006731 degradation reaction Methods 0.000 claims description 10
125000002795 guanidino group Chemical group C(N)(=N)N* 0.000 claims description 7
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 7
230000011382 collagen catabolic process Effects 0.000 claims description 6
239000007857 degradation product Substances 0.000 claims description 6
230000003301 hydrolyzing effect Effects 0.000 claims description 6
150000003839 salts Chemical class 0.000 claims description 5
239000000243 solution Substances 0.000 description 30
229920000159 gelatin Polymers 0.000 description 26
235000019322 gelatine Nutrition 0.000 description 26
WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 14
108010010803 Gelatin Proteins 0.000 description 13
239000001828 Gelatine Substances 0.000 description 13
238000006243 chemical reaction Methods 0.000 description 13
239000008273 gelatin Substances 0.000 description 13
235000011852 gelatine desserts Nutrition 0.000 description 13
238000010438 heat treatment Methods 0.000 description 12
235000002639 sodium chloride Nutrition 0.000 description 9
238000003756 stirring Methods 0.000 description 9
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
210000004369 blood Anatomy 0.000 description 6
239000008280 blood Substances 0.000 description 6
230000007062 hydrolysis Effects 0.000 description 6
238000006460 hydrolysis reaction Methods 0.000 description 6
239000011780 sodium chloride Substances 0.000 description 6
239000005057 Hexamethylene diisocyanate Substances 0.000 description 5
230000000890 antigenic effect Effects 0.000 description 5
230000029142 excretion Effects 0.000 description 5
RRAMGCGOFNQTLD-UHFFFAOYSA-N hexamethylene diisocyanate Chemical compound O=C=NCCCCCCN=C=O RRAMGCGOFNQTLD-UHFFFAOYSA-N 0.000 description 5
239000007858 starting material Substances 0.000 description 5
239000000126 substance Substances 0.000 description 5
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
KBPLFHHGFOOTCA-UHFFFAOYSA-N 1-Octanol Chemical compound CCCCCCCCO KBPLFHHGFOOTCA-UHFFFAOYSA-N 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 4
239000007795 chemical reaction product Substances 0.000 description 4
239000003795 chemical substances by application Substances 0.000 description 4
108090000623 proteins and genes Proteins 0.000 description 4
102000004169 proteins and genes Human genes 0.000 description 4
125000003277 amino group Chemical group 0.000 description 3
239000007864 aqueous solution Substances 0.000 description 3
239000004202 carbamide Substances 0.000 description 3
238000004821 distillation Methods 0.000 description 3
230000002349 favourable effect Effects 0.000 description 3
238000005187 foaming Methods 0.000 description 3
239000000499 gel Substances 0.000 description 3
230000002378 acidificating effect Effects 0.000 description 2
150000001413 amino acids Chemical class 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000008859 change Effects 0.000 description 2
239000000084 colloidal system Substances 0.000 description 2
230000002016 colloidosmotic effect Effects 0.000 description 2
125000005442 diisocyanate group Chemical group 0.000 description 2
230000000694 effects Effects 0.000 description 2
238000002474 experimental method Methods 0.000 description 2
238000001914 filtration Methods 0.000 description 2
238000001879 gelation Methods 0.000 description 2
LEQAOMBKQFMDFZ-UHFFFAOYSA-N glyoxal Chemical compound O=CC=O LEQAOMBKQFMDFZ-UHFFFAOYSA-N 0.000 description 2
235000015110 jellies Nutrition 0.000 description 2
239000008274 jelly Substances 0.000 description 2
230000007935 neutral effect Effects 0.000 description 2
239000003960 organic solvent Substances 0.000 description 2
239000005056 polyisocyanate Substances 0.000 description 2
229920001228 polyisocyanate Polymers 0.000 description 2
108090000765 processed proteins & peptides Proteins 0.000 description 2
230000001698 pyrogenic effect Effects 0.000 description 2
230000001954 sterilising effect Effects 0.000 description 2
238000004659 sterilization and disinfection Methods 0.000 description 2
238000003860 storage Methods 0.000 description 2
XSQUKJJJFZCRTK-UHFFFAOYSA-N urea group Chemical group NC(=O)N XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
LDXJRKWFNNFDSA-UHFFFAOYSA-N 2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]ethanone Chemical compound C1CN(CC2=NNN=C21)CC(=O)N3CCN(CC3)C4=CN=C(N=C4)NCC5=CC(=CC=C5)OC(F)(F)F LDXJRKWFNNFDSA-UHFFFAOYSA-N 0.000 description 1
206010002198 Anaphylactic reaction Diseases 0.000 description 1
229920002307 Dextran Polymers 0.000 description 1
229920000084 Gum arabic Polymers 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
102000057297 Pepsin A Human genes 0.000 description 1
108090000284 Pepsin A Proteins 0.000 description 1
239000004372 Polyvinyl alcohol Substances 0.000 description 1
241000978776 Senegalia senegal Species 0.000 description 1
102000004142 Trypsin Human genes 0.000 description 1
108090000631 Trypsin Proteins 0.000 description 1
239000000205 acacia gum Substances 0.000 description 1
235000010489 acacia gum Nutrition 0.000 description 1
239000002253 acid Substances 0.000 description 1
239000003929 acidic solution Substances 0.000 description 1
150000007513 acids Chemical class 0.000 description 1
150000001299 aldehydes Chemical class 0.000 description 1
125000001931 aliphatic group Chemical group 0.000 description 1
239000003513 alkali Substances 0.000 description 1
150000001408 amides Chemical class 0.000 description 1
238000004458 analytical method Methods 0.000 description 1
230000036783 anaphylactic response Effects 0.000 description 1
208000003455 anaphylaxis Diseases 0.000 description 1
150000008064 anhydrides Chemical class 0.000 description 1
239000002518 antifoaming agent Substances 0.000 description 1
125000003118 aryl group Chemical group 0.000 description 1
230000015572 biosynthetic process Effects 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
239000003633 blood substitute Substances 0.000 description 1
159000000007 calcium salts Chemical class 0.000 description 1
150000003841 chloride salts Chemical class 0.000 description 1
238000003776 cleavage reaction Methods 0.000 description 1
230000036569 collagen breakdown Effects 0.000 description 1
239000000470 constituent Substances 0.000 description 1
238000001816 cooling Methods 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
238000000909 electrodialysis Methods 0.000 description 1
230000008030 elimination Effects 0.000 description 1
238000003379 elimination reaction Methods 0.000 description 1
238000004108 freeze drying Methods 0.000 description 1
238000007710 freezing Methods 0.000 description 1
230000008014 freezing Effects 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
229940015043 glyoxal Drugs 0.000 description 1
230000006872 improvement Effects 0.000 description 1
239000012442 inert solvent Substances 0.000 description 1
238000002347 injection Methods 0.000 description 1
239000007924 injection Substances 0.000 description 1
IQPQWNKOIGAROB-UHFFFAOYSA-N isocyanate group Chemical group [N-]=C=O IQPQWNKOIGAROB-UHFFFAOYSA-N 0.000 description 1
239000000644 isotonic solution Substances 0.000 description 1
239000007788 liquid Substances 0.000 description 1
239000006193 liquid solution Substances 0.000 description 1
230000014759 maintenance of location Effects 0.000 description 1
239000000463 material Substances 0.000 description 1
238000005259 measurement Methods 0.000 description 1
WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
239000000203 mixture Substances 0.000 description 1
230000006855 networking Effects 0.000 description 1
231100000252 nontoxic Toxicity 0.000 description 1
239000001814 pectin Substances 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229940111202 pepsin Drugs 0.000 description 1
229920001184 polypeptide Polymers 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
229920002451 polyvinyl alcohol Polymers 0.000 description 1
229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
239000001267 polyvinylpyrrolidone Substances 0.000 description 1
235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
239000000843 powder Substances 0.000 description 1
102000004196 processed proteins & peptides Human genes 0.000 description 1
230000002035 prolonged effect Effects 0.000 description 1
230000002797 proteolythic effect Effects 0.000 description 1
239000011833 salt mixture Substances 0.000 description 1
230000007017 scission Effects 0.000 description 1
239000002904 solvent Substances 0.000 description 1
239000008223 sterile water Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
239000000725 suspension Substances 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
239000012588 trypsin Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
- C08G18/00—Polymeric products of isocyanates or isothiocyanates
- C08G18/06—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen
- C08G18/28—Polymeric products of isocyanates or isothiocyanates with compounds having active hydrogen characterised by the compounds used containing active hydrogen
- C08G18/40—High-molecular-weight compounds
- C08G18/64—Macromolecular compounds not provided for by groups C08G18/42 - C08G18/63
- C08G18/6415—Macromolecular compounds not provided for by groups C08G18/42 - C08G18/63 having nitrogen
- C08G18/6446—Proteins and derivatives thereof

Landscapes

Chemical & Material Sciences (AREA)
Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Molecular Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Zoology (AREA)
Gastroenterology & Hepatology (AREA)
Toxicology (AREA)
Epidemiology (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Chemical Kinetics & Catalysis (AREA)
Polymers & Plastics (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Materials For Medical Uses (AREA)

CH6857359A 1958-01-22 1959-01-20 Verfahren zur Herstellung von Blutplasmaersatzmitteln CH374695A (de)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DEF24857A DE1118792B (de)	1958-01-22	1958-01-22	Verfahren zur Herstellung von Blutplasmaersatzmitteln aus Kollagenabbauprodukten
DEF25921A DE1155134B (de)	1958-06-07	1958-06-07	Verfahren zur Herstellung von Blutplasmaersatzmitteln aus Kollagenabbauprodukten

Publications (1)

Publication Number	Publication Date
CH374695A true CH374695A (de)	1964-01-31

Family

ID=25974093

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
CH6857359A CH374695A (de)	1958-01-22	1959-01-20	Verfahren zur Herstellung von Blutplasmaersatzmitteln

Country Status (3)

Country	Link
BE (1)	BE575004A (fr)
CH (1)	CH374695A (fr)
OA (1)	OA02321A (fr)

1959
- 1959-01-20 CH CH6857359A patent/CH374695A/de unknown
- 1959-01-22 BE BE575004A patent/BE575004A/fr unknown
1967
- 1967-02-13 OA OA52757A patent/OA02321A/fr unknown

Also Published As

Publication number	Publication date
OA02321A (fr)	1970-05-05
BE575004A (fr)	1959-07-22

Publication	Publication Date	Title
DE2646968C2 (fr)	1988-01-07
DE69007057T2 (de)	1994-07-07	Verfahren zur Herstellung von Gelatine aus Fischhaut.
DE3750793T2 (de)	1995-04-13	Verfahren zur Behandlung von Kollagen zur Erleichterung seiner Vernetzung und das so erhaltene Kollagen.
DE69521653T2 (de)	2002-05-08	Verfahren zur Kontrolle der Strukturstabilität von Kollagenfasern hergestellt aus Lösungen und Dispersionen, behandelt mit Natriumhydroxid für die Deaktivierung von infektiösen Wirkstoffen
DE69711540T3 (de)	2007-02-01	Lösungsmittel-getrocknete Polysaccharidschwämme
DE69429522T2 (de)	2002-08-01	Injizierbare zusammensetzungen zur vergrösserung von weichgewebe
DE69632313T2 (de)	2004-09-09	Desorbierbare extrazelluläre matrix für rekonstruktion eines knorpelgewebes
DE3034273C2 (fr)	1990-03-22
DE3688188T2 (de)	1993-10-14	Verfahren zur Herstellung einer Formulierung mit verzögerter Freisetzung.
DE4028622C2 (de)	1994-01-27	Verfahren zum Herstellen von Kollagenschwämmen
DE1642578B2 (de)	1974-02-14	Verfahren zur Herstellung einer enzymatischen Zusammensetzung mit proteolytischem Enzym und Kollagenase-Aktivität
DE1949195A1 (de)	1970-07-30	Verfahren zur Herstellung deproteinisierter Bluextrakte mit Heilwirkung
DE3024356A1 (de)	1981-01-22	Verfahren zur senkung der geliertemperatur von aus milch erhaltenen molkeproteinen
DE2348294C3 (de)	1980-08-21	Modifizierte Gelatine mit erniedrigtem Gelschmelzpunkt
DE1155134B (de)	1963-10-03	Verfahren zur Herstellung von Blutplasmaersatzmitteln aus Kollagenabbauprodukten
AT212493B (de)	1960-12-27	Verfahren zur Herstellung von Blutplasmaersatzmitteln
DE1118792B (de)	1961-12-07	Verfahren zur Herstellung von Blutplasmaersatzmitteln aus Kollagenabbauprodukten
CH374695A (de)	1964-01-31	Verfahren zur Herstellung von Blutplasmaersatzmitteln
DE2505814C2 (de)	1984-11-15	Verfahren zur Herstellung feinverteilter Mikropartikel von Tyrosin mit einem Gehalt eines darin dispergierten, mit Glutaraldehyd modifizierten Allergens und diese Mikropartikel als Wirkstoff enthaltende injizierbare Lösung
AT214071B (fr)	1961-03-10
AT392003B (de)	1991-01-10	Verfahren zur herstellung eines insbesondere zur wundheilung oder zur behandlung in der geriatrie verwendbaren wirkstoffes aus saeugetierblut durch papainhydrolyse und ein einen solchen wirkstoff enthaltendes praeparat
DE657129C (de)	1938-02-24	Verfahren zur Herstellung von Loesungen oder Extrakten aus Bakterien, Pollen oder sonstigen pflanzlichen Zellen
DE102010037469A1 (de)	2012-03-15	Verfahren zur Reduzierung des Endotoxingehalts in einem kollagenhaltigen Material
DE437001C (de)	1926-11-15	Verfahren zur Darstellung von Abbauprodukten aus Keratinsubstanzen
DE914423C (de)	1954-07-01	Verfahren zur Herstellung von als Blutplasma-Ersatz geeigneten Zubereitungen